Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

113.13 +4.90 (+4.53%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biontech Se ADR

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
65 66 Next >
FDA To Hold Advisory Committee Meeting To Discuss COVID-19 Vaccine Future Boosters
The FDA that a panel of independent advisers will meet on April 6 to discuss considerations for using COVID-19 vaccine booster doses. 
Via Benzinga
Will Another Covid Booster Save Vaccine Stocks Moderna, BioNTech?
Vaccine stocks remain under pressure despite a push for another round of Covid shots. 
Via Investor's Business Daily
5 Value Stocks To Watch In The Healthcare Sector
What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E... 
Via Benzinga
Health Experts Forecast Increase In COVID-19 Cases In US Amid New Omicron Subvariant: CNBC
U.S. health experts warn that an emerging, highly contagious COVID-19 omicron variant, BA.2, could soon increase domestic coronavirus cases. 
Via Benzinga
Maker Of Pfizer's COVID-19 Vaccine mRNA-Delivery Tech Sues Arbutus Biopharma: Reuters
Canada-based Acuitas Therapeutics Inc has sued Arbutus Biopharma Corporation (NASDAQ: ABUS) in Manhattan federal court, seeking to head off claims that the vaccine infringes Arbutus' patents,  
Via Benzinga
Is A Fourth Covid Shot Needed? Pfizer, Moderna Say Yes And Request It
Moderna just asked the FDA to sign off on another booster shot for all adults. 
Via Investor's Business Daily
The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Like Pfizer, Moderna Seeks FDA Approval For Fourth COVID-19 Shot Or Second Booster Dose
Moderna Inc (NASDAQ: MRNA) has asked the FDA to authorize a  
Via Benzinga
Vaccine Makers Continue to Post Big Stock Price Gains
As Barron’s reports: “According to a data tracker from the New York Times, the daily average number of new cases in China is up more than 450% over the past two weeks.” 
Via Talk Markets
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
WHO Foundation Warns Global Economy To Lose "Trillions Of Dollars" On COVID-19 Vaccine Inequality: CNBC
The WHO Foundation CEO, Anil Soni, has told CNBC that the global economy will lose “trillions of dollars” if more COVID-19 vaccines aren& 
Via Benzinga
White House Warns It Cannot Afford COVID-19 Related Solutions If Cases Increase: FT
The White House says that the U.S. is running out of money to pay for COVID-19 vaccines, tests, and treatments, making it unprepared for any rising cases in the future. 
Via Benzinga
Pfizer-BioNTech Seek FDA Approval For Second COVID-19 Booster In Elderly Population
Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) filed an application with the  
Via Benzinga
Hopes For A Peace Accord
The winner today was BioNTech up 14.89% on hopes for new sales for the Covid-19 variant. 
Via Talk Markets
96 Biggest Movers From Yesterday
Gainers Volt Information Sciences, Inc. (NYSE: VOLT) shares surged 94.7% to close at $5.88 on Monday after the company announced it would be acquired for $6 per share. Incannex... 
Via Benzinga
Vaccine Stocks Pfizer, Moderna Pop As 'Deltacron' Emerges, China Locks Down
Pfizer CEO Albert Bourla says a fourth booster shot is needed "right now." 
Via Investor's Business Daily
Why Is Novavax (NVAX) Stock in the Spotlight Today?
Novavax is once again in the spotlight as China reports near-record numbers of Covid cases. What's going on with NVAX stock? 
Via InvestorPlace
Here's Why BioNTech Shares Are Rising On Monday
BioNTech SE - ADR (NASDAQ: BNTX) shares are trading higher by 14.8% at $155.65. Strength is possibly due to a spike in COVID-19 cases in China, which could lift vaccine sector sentiment. 
Via Benzinga
Mid-Afternoon Market Update: Dow Turns Negative; Turquoise Hill Resources Shares Spike Higher
U.S. stocks turned lower toward the end of trading on Monday as the Dow Jones dropped 100 points, after surging more than 400 points earlier during the session. The Dow... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Incannex Healthcare (NASDAQ:IXHL) stock moved upwards by 48.0% to $20.95 during Monday's regular session. The company's market cap stands at $1.0 billion.... 
Via Benzinga
GeoVax Labs Retains CATO SMS To Manage Its Mid-Stage COVID-19 Vaccine Trials
GeoVax Labs Inc (NASDAQ: GOVX) has engaged CATO SMS to manage its two ongoing Phase 2 trials of its COVID-19 vaccine candidate, GEO-CM04S1. One is testing the... 
Via Benzinga
50 Stocks Moving In Monday's Mid-Day Session
Gainers Volt Information Sciences, Inc. (NYSE: VOLT) shares jumped 95.2% to $5.89 after the company announced it would be acquired for $6 per share. AgriFORCE Growing Systems,... 
Via Benzinga
Pfizer-BioNTech's COVID-19 Shot Moderately Effective Against Omicron In Kids Aged 5 to 15, CDC Study Shows
The Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX) vaccine is only moderately effective against the omicron variant when tested in children ages 5 to 15.... 
Via Benzinga
Vaccine Stocks BioNTech, Moderna Pop On Fourth Dose — But IBD/TIPP Poll Says Few People Care
The IBD/TIPP Poll shows Covid has fallen among Americans' priorities. 
Via Investor's Business Daily
BioNTech, Regeneron To Evaluate FixVac-Based Cancer Vaccine/Libtayo Combo In NSCLC
BioNTech SE (NASDAQ: BNTX) has expanded its strategic collaboration with Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to its FixVac candidate BNT116... 
Via Benzinga
Benzinga Bulls And Bears Of The Past Week: Shopify, Palantir, Apple, Meta, Twitter, Johnson & Johnson, American Express And More
Benzinga has examined the prospects for many investor favorite stocks over the... 
Via Benzinga
Johnson & Johnson's COVID-19 Vaccine Less Effective Against Hospitalization, French Study Shows
According to a large French study, the risk of hospitalization after vaccination with Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine was about five times... 
Via Benzinga
Markets Fall As Russia-Ukraine Tensions Escalate; American Express, Boeing See Sharp Drops
U.S. indices finished lower as the Russian invasion of Ukraine continues to escalate. The conflict has weighed on stocks and economic sentiment whi... 
Via Benzinga
Pfizer/BioNTech's COVID-19 Vaccine Mere 12% Effective In Kids 5-11 Years, New York Study Shows
According to a published study, Pfizer Inc (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX) two-dose COVID-19 vaccine provided very little protection for... 
Via Benzinga
DarioHealth Enters Into Strategic Agreement With Sanofi U.S.
Novel Strategic Agreement focuses on commercial growth for Dario and the development of Digital Health Solutions on Dario’s platform. 
Via Talk Markets
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.